Naobios: a 15 Years history of an expertise in cell culture and virus production.

2019 and beyond

a new history of Contract Development and Manufacture for global sponsors

On March 1st, 2019, BE Vaccines was acquired by Clean Biologics, a group owning the company Clean Cells (specialist in quality control testing and in the manufacture of starting material), and was rebranded as Naobios. The new company operates as CDMO (“Contract Development and Manufacturing Organization”) with a mission: to undertake the process development and GMP manufacture of preclinical and clinical batches of viral vaccines and viral vectors using the expertise gathered over 15 years of existence in various companies.

The Naobios team currently consists of 47 people who form a versatile and experienced group in the use of suspension or adherent cells for the production of viral vaccines and viral vectors. The group develops scalable processes and manufactures GMP product in a high-end facility with innovative technologies.

2013 to 2019

consolidation of an international GMP experience and handling of sensitive products

In November 2013, the site was acquired from Valneva (formerly Vivalis) by Biological E Limited (India) to become BE Vaccines SAS and to support the vaccines pipeline technical development, GMP production and technical transfer to India.

In 2014, a facility expansion increased the production capabilities and efficiency by creating a fourth clinical manufacturing area with BSL2+ containment requirements and a new biostorage area.

In 2016, the warehouse was moved to an external location to create new offices and meeting rooms.

2005 to 2013

Construction of the site and development of a specialized know-how

The Naobios site is located in Saint-Herblain, north-west of Nantes (France). It was built in 2005 by Vivalis, for cell line development, R&D activities and GMP activities for early stage biological product development.